Novavax

Novavax is the post-pandemic vaccine company everyone forgot. The story has flipped three times in five years. In 2020 it was the great hope. By 2022 the market dismissed it. In May 2024, Sanofi paid 500 million USD upfront plus up to 700 million USD in milestones plus royalties for co-commercialization of Nuvaxovid (NVX-CoV2373), the protein-subunit COVID vaccine. That single deal cleared the cash crisis, gave Novavax a partner with global distribution, and let management focus on the pipeline rather than survival.

The trailing P/E of 0.0 reflects ongoing losses; forward P/E -16.7 reflects analyst expectation of continued losses through 2026. Revenue declined 79.1 percent year over year — the COVID base-effect that every former pandemic-beneficiary has now lived through. What is left after that decline matters more than the decline itself.

What remains: the Matrix-M adjuvant platform (used in the GSK R21 Mosquirix malaria vaccine licensed by Serum Institute), a Sanofi partnership royalty stream, an avian-flu (H5N1) candidate, and a Phase 3 combined COVID-influenza shot. 749 employees, 1.49 billion USD market cap, current ratio 2.48, debt-to-equity 0.0. The capital structure is unusually clean for a beat-up biotech.

13F filings show no smart-money clustering. Institutional ownership is dominated by passive vehicles. Short interest of 30.28 percent (short ratio 15.57 days to cover) signals heavy bearish positioning — typical for binary biotechs where the short thesis is dilution or pipeline failure. The mirror image: any positive milestone announcement triggers a short squeeze given the cover-time math.

EV/EBITDA 16.71 and EV/Revenue 1.67 mask the fact that the underlying business model is shifting from product sales to royalty income. On a sum-of-parts basis: Sanofi royalty stream (mid-teens on 2026E Nuvaxovid revenue of 800 million to 1.2 billion USD) is worth roughly 1.5 to 2.5 billion USD on a 10x multiple. Matrix-M licensing including the R21 malaria royalty is worth another 500 million to 1 billion USD. Pipeline optionality (avian flu, COVID-flu combo) is a free option at the current 1.49 billion USD market cap. Analyst price target mean 14.11 USD implies 55.8 percent upside; high target 25.00 USD reflects the bull case where the pipeline delivers one product.

1. :
2. :
3. :

Novavax is a binary option on Sanofi execution plus pipeline. The Sanofi deal converted it from a default-risk biotech into something closer to a Matrix-M adjuvant royalty company with COVID legacy. The 30 percent short interest is the meaningful number: shorts are paid to be right, and they are still short. If Sanofi delivers 1 billion USD of Nuvaxovid sales in 2026 and the COVID-flu combo Phase 3 reads out positive, the stock can easily double. If either disappoints, dilution risk returns. Position sizing should reflect the binary nature: this is not a 5 percent of portfolio decision, it is a 1 percent of portfolio decision.